|
Gastroenterology
Large-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B
Chang Wook Kim, Chang Seop Kim, Hee Yeon Kim, Chang Don Lee, Kyungha Yu, Cyril Llamoso, Heon Ju Lee
Korean J Intern Med. 2018;33(1):91-101. Published online December 13, 2017
Background/Aims: Entecavir (ETV) is effective and safe antiviral agent against hepatitis B virus (HBV) in clinical and real-world setting but, most studies were performed in single institute or have limitation in patient’s number. A large-scale nation-wide real-world surveillance study was carried..
|
|
|
Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line
hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response
Ju-Yeon Cho, Won Sohn, Dong-Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo, Joon Hyeok Lee
Korean J Intern Med. 2017;32(4):636-646. Published online November 4, 2016
Background/Aims: Entecavir is a potent nucleoside analogue with high efficacy and barrier for resistance. We aimed to investigate the long-term efficacy and viral resistance rate of entecavir and explore the factors associated with virologic response, including quantitative hepatitis B surface anti..
|
|
|
Long-term virological outcome in chronic hepatitis B patients with a partial virological response to entecavir
Yu Jung Jo, Kyung-Ah Kim, June Sung Lee, Nam-Hoon Kim, Won Ki Bae, Tae June Song, Jeong Wook Kim
Korean J Intern Med. 2015;30(2):170-176. Published online February 27, 2015
Background/Aims: The clinical outcome of patients with a partial virological response (PVR) to entecavir (ETV), in particular nucloes(t)ide analogue (NA)-experienced patients, has not been thoroughly investigated. The aim of the present study was to assess long-term outcomes in NA-naive and NA-exper..
|
|
|
